There are currently 99 inhalation devices in the UK market for respiratory diseases. These products are either monotherapy or fixed-dose combinations of beta-agonists, anti-muscarinics, mast-cell stabilizers and inhaled corticosteroids (ICS). This research evaluates the potential challenges in choosing the right device by physicians and patients.
Authors: George Wang, Richard Macaulay
To find out more about this poster you can register to download it here after the ISPOR event.